Title
Intranasal cotinine improves memory, and reduces depressive-like behavior, and GFAP + cells loss induced by restraint stress in mice
Date Issued
01 September 2017
Access level
metadata only access
Resource Type
research article
Author(s)
Perez-Urrutia N.
Mendoza C.
Alvarez-Ricartes N.
Oliveros-Matus P.
Echeverria F.
Grizzell J.A.
Iarkov A.
Echeverria V.
Pontificia Universidad Javeriana
Abstract
Posttraumatic stress disorder (PTSD), chronic psychological stress, and major depressive disorder have been found to be associated with a significant decrease in glial fibrillary acidic protein (GFAP) immunoreactivity in the hippocampus of rodents. Cotinine is an alkaloid that prevents memory impairment, depressive-like behavior and synaptic loss when co-administered during restraint stress, a model of PTSD and stress-induced depression, in mice. Here, we investigated the effects of post-treatment with intranasal cotinine on depressive- and anxiety-like behaviors, visual recognition memory as well as the number and morphology of GFAP + immunoreactive cells, in the hippocampus and frontal cortex of mice subjected to prolonged restraint stress. The results revealed that in addition to the mood and cognitive impairments, restraint stress induced a significant decrease in the number and arborization of GFAP + cells in the brain of mice. Intranasal cotinine prevented these stress-derived symptoms and the morphological abnormalities GFAP + cells in both of these brain regions which are critical to resilience to stress. The significance of these findings for the therapy of PTSD and depression is discussed.
Start page
211
End page
221
Volume
295
Language
English
OCDE Knowledge area
Neurociencias
Subjects
Scopus EID
2-s2.0-85020889285
PubMed ID
Source
Experimental Neurology
ISSN of the container
00144886
Sponsor(s)
This material is the result of work supported with resources and the use of facilities at the Bay Pines VA Healthcare System. The contents do not necessarily represent the views of the Department of Veterans Affairs or the United States Government. Also, we thank Dr. William Fray and Dr. Leha Hanson from the Alzheimer's Research Center at Regions Hospital, HealthPartners Research Foundation for providing training and guidance with the implementation of intranasal delivery of drugs to mice. We would also like to thank Drs. Lowell Gaertner and Matthew Cooper from the University of Tennessee for advice on statistical analyses. Funding: This work was supported by the Fondo de Ciencia y Tecnologia (FONDECYT) de Chile, grant 1150149.
Sources of information:
Directorio de Producción Científica
Scopus